Telix Pharmaceuticals (ASX:TLX) does not expect any material impact on its business or supply chain from the international trade tariffs announced by the US government on April 2, according to a Monday Australian bourse filing.
It noted that it had an extensive US-based manufacturing and distribution infrastructure with third-party manufacturing sites and radiopharmacy partner networks. Pharmaceutical products are currently exempt from the tariffs.
The firm also said that the Food and Drug Administration continues to process applications and information requests, despite reports of changes at the agency, and that the firm has not been notified of any changes to the timelines for its new drug application for Pixclara or biologics license application for Zircaix.
Its shares fell 4% in recent trading on Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。